# bioAffinity Technologies, Inc.: overview BIAF · Nasdaq · CIK 1712762 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/biaf.md) · [Financials](/companies/biaf/financials.md) · [Filings](/companies/biaf/filings.md) · [Insiders](/companies/biaf/insiders.md) Latest reported revenue: [$1.5m](/filings/0001493152-26-036619.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-036619). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,350](/filings/0001493152-25-023405.md) | [2,208 d](/filings/0001493152-26-010143.md) | [1,854](/filings/0001493152-26-022044.md) | [1,269](/filings/0001493152-26-036619.md) | [1,446](/filings/0001493152-25-023405.md) | [1,593 d](/filings/0001493152-26-010143.md) | [1,352](/filings/0001493152-26-022044.md) | [1,511](/filings/0001493152-26-036619.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(84.0%)](/filings/0001493152-25-023405.md) | [(133.5%) d](/filings/0001493152-26-010143.md) | [(141.7%)](/filings/0001493152-26-022044.md) | [(198.2%)](/filings/0001493152-26-036619.md) | [(158.6%)](/filings/0001493152-25-023405.md) | [(196.9%) d](/filings/0001493152-26-010143.md) | [(267.6%)](/filings/0001493152-26-022044.md) | [(220.8%)](/filings/0001493152-26-036619.md) | | Net margin | % | [(85.1%)](/filings/0001493152-25-023405.md) | [(134.4%) d](/filings/0001493152-26-010143.md) | [(143.5%)](/filings/0001493152-26-022044.md) | [(319.9%)](/filings/0001493152-26-036619.md) | [(349.3%)](/filings/0001493152-25-023405.md) | [(197.0%) d](/filings/0001493152-26-010143.md) | [(268.6%)](/filings/0001493152-26-022044.md) | [(222.8%)](/filings/0001493152-26-036619.md) | | Diluted EPS | $ per share | [(4.84)](/filings/0001493152-25-023405.md) | not reported | [(4.80)](/filings/0001493152-26-022044.md) | [(5.07)](/filings/0001493152-26-036619.md) | [(4.74)](/filings/0001493152-25-023405.md) | not reported | [(0.81)](/filings/0001493152-26-022044.md) | [(0.64)](/filings/0001493152-26-036619.md) | | Free cash flow | $k | [(1,719) d](/filings/0001493152-25-023405.md) | [(1,677) d](/filings/0001493152-26-010143.md) | [(1,693)](/filings/0001493152-26-022044.md) | [(2,661) d](/filings/0001493152-26-036619.md) | [(2,484) d](/filings/0001493152-25-023405.md) | [(2,560) d](/filings/0001493152-26-010143.md) | [(3,233)](/filings/0001493152-26-022044.md) | [(3,291) d](/filings/0001493152-26-036619.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [4.8](/filings/0001493152-24-012358.md) | [2,532](/filings/0001641172-25-001840.md) | [9,362](/filings/0001493152-26-010143.md) | [6,162](/filings/0001493152-26-010143.md) | | Gross margin | % | not reported | [90.3%](/filings/0001493152-23-010186.md) | not reported | not reported | not reported | | Operating margin | % | not reported | [(83511.5%)](/filings/0001493152-24-012358.md) | [(314.8%)](/filings/0001641172-25-001840.md) | [(95.6%)](/filings/0001493152-26-010143.md) | [(171.6%)](/filings/0001493152-26-010143.md) | | Net margin | % | not reported | [(169771.2%)](/filings/0001493152-24-012358.md) | [(313.4%)](/filings/0001641172-25-001840.md) | [(96.6%)](/filings/0001493152-26-010143.md) | [(242.0%)](/filings/0001493152-26-010143.md) | | Diluted EPS | $ per share | not reported | [(1.81)](/filings/0001493152-24-012358.md) | [(0.91)](/filings/0001641172-25-001840.md) | [(22.50)](/filings/0001493152-26-010143.md) | [(8.66)](/filings/0001493152-26-010143.md) | | Free cash flow | $k | not reported | [(4,291)](/filings/0001493152-24-012358.md) | [(6,061)](/filings/0001641172-25-001840.md) | [(7,344)](/filings/0001493152-26-010143.md) | [(9,389)](/filings/0001493152-26-010143.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/biaf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $7.7k | 54,927 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $6.5k | 46,445 | | Added +336 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $2.4k | 17,162 | | Reduced −2,688 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.6k | 11,180 | | Added +167 | ## Recent filings [All 397 filings](/companies/biaf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 08:30 ET | [8-K](/filings/0001493152-26-049188.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-049188 | | 2026-10-23 | 16:30 ET | [DEF 14A](/filings/0001493152-26-048245.md) | Proxy statement, period 2026-10-23 | 0001493152-26-048245 | | 2026-10-15 | 09:30 ET | [8-K](/filings/0001493152-26-047168.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-047168 | | 2026-10-13 | 09:23 ET | [8-K](/filings/0001493152-26-046755.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-046755 | | 2026-10-09 | 16:30 ET | [8-K](/filings/0001493152-26-046548.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-046548 | | 2026-10-08 | 08:30 ET | [8-K](/filings/0001493152-26-046266.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-046266 | | 2026-10-06 | 08:30 ET | [8-K](/filings/0001493152-26-045867.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-045867 | | 2026-09-30 | 08:30 ET | [8-K](/filings/0001493152-26-045034.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-045034 | | 2026-09-22 | 08:30 ET | [8-K](/filings/0001493152-26-043654.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-043654 | | 2026-09-17 | 08:30 ET | [8-K](/filings/0001493152-26-043052.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-043052 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010143.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b902cc32-d47d-46b9-9549-1d8b795a4e7b) ## About the filer - CIK: 1712762 - Tickers: BIAF, BIAFW - Exchange: Nasdaq - SIC code: 8731 Services-Commercial Physical & Biological Research - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:32 ET. No prices; not investment advice.